EPELSIBAN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H38N4O4
Molecular Weight	518.6471
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC[C@H](C)[C@H]1N([C@@H](C(=O)N2CCOCC2)C3=C(C)N=C(C)C=C3)C(=O)[C@H](NC1=O)C4CC5=CC=CC=C5C4

InChI

InChIKey=UWHCWRQFNKUYCG-QUZACWSFSA-N

InChI=1S/C30H38N4O4/c1-5-18(2)26-28(35)32-25(23-16-21-8-6-7-9-22(21)17-23)29(36)34(26)27(24-11-10-19(3)31-20(24)4)30(37)33-12-14-38-15-13-33/h6-11,18,23,25-27H,5,12-17H2,1-4H3,(H,32,35)/t18-,25+,26+,27+/m0/s1

HIDE SMILES / InChI

Description

Epelsiban (GSK557296), a pyridyl-2,5-diketopiperazine, is a potent, highly selective, and orally bioavailable non-peptide oxytocin receptor antagonist. GlaxoSmithKline was developing epelsiban for the treatment of women infertility due to adenomyosis and premature ejaculation.

Originator

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Oxytocin receptor 19	Antagonist 2,849		9.9 null [pKi]

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

phase I studies: at total daily doses of 600 and 900 mg, epelsiban was generally well tolerated, and there were no significant safety concerns identified.

Route of Administration: Oral

Show entries

Name

Type

Language

EPELSIBAN

Official Name

English

epelsiban [INN]

Preferred Name

English

2,5-PIPERAZINEDIONE, 3-(2,3-DIHYDRO-1H-INDEN-2-YL)-1-((1R)-1-(2,6-DIMETHYL-3-PYRIDINYL)- 2-(4-MORPHOLINYL)-2-OXOETHYL)-6-((1S)-1-METHYLPROPYL)-, (3R,6R)-

Common Name

English

GSK557296

Code

English

3R,6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-1-((1R)-1-(2,6-DIMETHYLPYRIDIN-3-YL)-2-(MORPHOLIN-4-YL)-2-OXOETHYL)-6-((1S)-1-METHYLPROPYL)PIPERAZINE-2,5-DIONE

Common Name

English

Showing 1 to 5 of 11 entries

Previous1 2 3Next

Show entries

Classification Tree